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Abstract  Oxytocin  is  the  uterotonic  agent  of  choice  in  the  prevention  and  treatment  of  post-
partum uterine  atony.  Nevertheless,  there  is  no  consensus  on  the  optimal  dose  and  rate  for
use in  cesarean  sections.  The  use  of  high  bolus  doses  (e.g.,  10  IU  of  oxytocin)  can  determine
deleterious  cardiovascular  changes  for  the  patient,  especially  in  situations  of  hypovolemia  or
low cardiac  reserve.  Furthermore,  high  doses  of  oxytocin  for  prolonged  periods  may  lead  to
desensitization  of  oxytocin  receptors  in  myometrium,  resulting  in  clinical  inefﬁciency.
© 2016  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Ocitocina  em  cesarianas.  O  que  há  de  novo?
Resumo  A  ocitocina  é  o  uterotônico  de  primeira  escolha  na  prevenc¸ão  e  no  tratamento  da
atonia uterina  após  o  parto.  Apesar  disso,  não  existe  consenso  sobre  qual  a  dose  e  velocidade
ideais de  seu  uso  em  cesarianas.  O  uso  de  altas  doses  (por  exemplo,  10  UI  de  ocitocina)  em  bolus
pode determinar  alterac¸ões  cardiocirculatórias  deletérias  para  a  paciente,  especialmente  em
situac¸ões de  hipovolemia  ou  baixa  reserva  cardíaca.  Além  disso,  altas  doses  de  ocitocina  por
períodos prolongados  podem  levar  à  dessensibilizac¸ão  dos  receptores  de  ocitocina  localizados
no miométrio  e  resultar  em  ineﬁcácia  clínica.
© 2016  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Este
é um  artigo  Open  Access  sob  a  licença  de  CC  BY-NC-ND  (http://creativecommons.org/
Ilicenses/by-nc-nd/4.0/).∗ Corresponding author.
E-mail: eduardo@hu.usp.br (E.T. Yamaguchi).
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Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)ntroductionxytocin,  the  ﬁrst  polypeptide  hormone  to  be  synthesized
n  1953  by  Vincent  Du  Vigneau,  is  the  drug  of  choice  for
oth  prevention  and  treatment  of  uterine  atony  after
hildbirth.1 Oxytocin  binds  to  its  receptor  on  the  surface
Elsevier Editora Ltda. This is an open access article under the CC
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of  the  myometrium  cell,  interacts  with  phospholipase  C,
and  generates  diacylglycerol  and  inositol  triphosphate.
Diacylglycerol  leads  to  the  synthesis  of  prostaglandins,
important  in  the  mechanism  of  contraction,  while  inos-
itol  triphosphate  increases  calcium  concentration  in  the
cell  sarcoplasmic  reticulum,  thereby  determining  the
contraction  of  myometrium.
Uterine  atony  is  the  leading  cause  of  postpartum  bleed-
ing,  which  gives  oxytocin  an  important  role  in  reducing  the
severity  of  uterine  bleeding  and  hence  maternal  mortal-
ity.  According  to  the  website  of  the  Ministry  of  Health,  a
clear  decrease  (69.3%)  in  the  risk  of  maternal  death  from
hemorrhage  occurred  in  Brazil  between  1990  and  2010.2
The  best  training  of  professionals  involved  in  the  care  of
these  women,  as  well  as  the  rational  use  of  available  drugs
to  prevent  or  treat  uterine  atony  (such  as  oxytocin,  for
example)  may  be  one  of  the  factors  responsible  for  this
reduction.
The  aim  of  this  review  was  to  update  the  article  on
the  use  of  oxytocin  in  cesarean  sections  published  by  these
authors  seven  years  ago.3 A  literature  search  in  PubMed
database  was  performed  with  the  keywords  ‘‘oxytocin’’
and  ‘‘cesarean  section’’  up  to  April  2013,  with  prefer-
ence  to  articles  published  from  2007  (year  of  the  previous
review  publication).  The  authors  selected  the  items  con-
sidered  most  relevant  to  the  practice  of  anesthesiologists,
besides  obtaining  possible  references  from  the  articles  ini-
tially  selected.
Use in cesarean sections
Despite  being  a  fairly  common  practice,  oxytocin  is  used
in  cesarean  sections  empirically.  Surprisingly,  to  date  there
is  no  consensus  about  the  ideal  regime  of  its  administra-
tion,  even  after  60  years  of  its  synthesis  and  routine  use  in
obstetric  centers.  An  example  is  the  study  by  Wedisinghe
et  al.,4 in  which  they  reported  the  existence  of  at  least  38
different  regimens  of  oxytocin  infusion  in  the  UK.  Although
there  is  no  such  documentation,  this  fact  does  not  seem  to
be  very  different  from  what  happens  in  Brazilian  medical
institutions.
The  variability  of  doses  and  infusion  rates  of  oxy-
tocin  complicates  a  meta-analysis  that  contribute  to  the
establishment  of  a  consensus  on  the  best  use  of  oxy-
tocin  to  prevent  postpartum  bleeding.5 Anyway,  it  must
be  remembered  that  oxytocin  is  used  prophylactically  in
most  obstetric  patients  as  supplementation  of  endogenous
oxytocin.  Thus,  the  use  of  high  doses  (either  by  bolus  or
continuous  infusion)  would  be  unnecessary  and  even  detri-
mental  to  patients  due  to  the  possibility  of  side-effects
(particularly  cardiovascular).
Butwick  et  al.6 attempted  to  ﬁnd  the  minimum  effective
dose  (ED)  of  oxytocin  that  would  determine  a  satisfactory
uterine  contractility  during  elective  cesarean  section.  To
this  end,  75  pregnant  women  primigravidae  and  without  risk
factors  for  developing  uterine  atony  were  evaluated  with
logistic  regression  method.  The  authors  concluded  that  sat-
isfactory  uterine  contractility  could  be  obtained  with  the  use
of  low-dose  oxytocin  bolus  (0.5--3  IU).  The  calculation  of  ED
to  promote  uterine  contraction  in  50%  (ED50)  and  90%  (ED90)
of  patients  was  possible  because,  curiously,  the  uterine
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one  was  evaluated  as  satisfactory  in  73%  of  cases  by  the
bstetric  team  in  placebo  group  (without  oxytocin).  It  is  pos-
ible  that  this  fact  has  occurred  due  to  the  uterine  massage
erformed  by  the  obstetrician  for  the  uterus  externaliza-
ion.  However,  the  isolated  uterine  massage  does  not  spare
he  use  of  oxytocin  because  the  placebo  group  required
escue  oxytocin.  This  conﬁrms  that  the  optimum  approach
s  the  combination  of  prophylactic  oxytocin  and  uterine
assage.
Oxytocin  administration  by  continuous  infusion  in
esarean  section  reduces  the  need  for  using  other  uterotonic
gents.  Sheehan  et  al.7 performed  a prospective,  random-
zed,  multicenter  study  in  Ireland  with  2069  women  who
nderwent  elective  cesarean  section.  All  patients  received
xytocin  5  IU  in  one  minute,  followed  by  oxytocin  40  IU
iluted  in  500  mL  saline  for  four  hours  or  saline  alone
placebo  group).  Although  the  infusion  of  oxytocin  have
ot  affected  the  general  occurrence  of  obstetrical  bleed-
ng,  there  was  a  signiﬁcant  reduction  in  the  need  for  other
terotonic  agents  with  the  use  of  bolus  followed  by  infusion
f  oxytocin  compared  with  the  use  of  oxytocin  bolus  alone
12.2%  vs.  18.4%;  p  <  0.001).
Thus,  the  use  of  low-dose  oxytocin  bolus  does  not  spare
he  use  of  continuous  infusion  of  oxytocin.  Although  there
s  no  record  on  that  probably  the  use  of  oxytocin  continu-
us  infusion  alone  (diluted  in  saline  and  controlled  by  drip),
hat  is,  without  initial  bolus,  is  the  approach  most  commonly
sed  by  Brazilian  anesthesiologists.  George  et  al.8 studied  50
atients  undergoing  elective  cesarean  section  without  risk
actors  for  uterine  atony.  The  authors  showed  that  oxytocin
D90 in  these  patients  was  0.29  IU  min−1,  which  is  equivalent
o  diluting  15  IU  of  oxytocin  in  1  L  saline  and  infuse  this  solu-
ion  in  1  h.  These  results  correspond  to  50%  less  than  the
reviously  used  infusion  at  the  institution  where  the  study
as  conducted.  However,  due  to  the  large  variation  of  the
onﬁdence  interval  (95%  CI,  0.15--0.43  IU  min−1),  this  ED90
stimate  may  be  inaccurate.  Thus,  other  studies  are  needed
o  conﬁrm  these  results.
King  et  al.9 unlike  the  previously  mentioned  authors,
valuated  patients  who  had  at  least  one  risk  factor  for  the
evelopment  of  uterine  atony  (uterine  distention,  prolonged
xposure  to  oxytocin  prior  to  cesarean  section,  chorioam-
ionitis,  and  others).  The  use  of  initial  bolus  of  oxytocin
5  IU),  followed  by  oxytocin  infusion  (40  IU  in  500  mL  saline
nfused  over  30  min,  followed  by  20  IU  in  1  L  over  8  h)  did
ot  alter  the  need  for  other  uterotonic  agent  in  the  ﬁrst
4  h  after  cesarean  section,  when  compared  with  infusion
lone.
With  the  risks  and  beneﬁts  of  using  oxytocin  as  a  base,
sen  and  Balki10 proposed  a  management  regime  based  on
vidence  and  called  ‘‘rule  of  threes’’.  The  authors  sug-
est  the  use  of  3  IU  of  intravenous  oxytocin  (administered
t  higher  speed  than  15  s)  as  the  starting  dose,  which  may
e  repeated  two  more  times  (in  three  minute  intervals)  if
terine  tone  is  not  satisfactory.  The  oxytocin  maintenance
ose  is  3  IU  L−1 at  100  mL  h−1.xtrauterine actions
uch  more  complex  than  previously  thought,  the  extrauterin
ctions  of  oxytocin  go  beyond  the  cardiovascular  system.
4F
w
t
a
o
o
(
t
t
s
c
p
u
d
r
t
i
o
d
m
T
a
v
m
n
c
r
h
o
(
i
t
m
o
d
e
ﬁ
d
a
o
e
h
i
a
a
i
s
(
a
a
T
t
t
b
d
e
o
i
(
s
a
m
w
l
4
c
l
t
t
r
t
r
b
o
c
h
r
o
m
p
p
c
i
i
(
d
5
4
w
s
u
s
s
s
2
(
p
o
u
t
o
h
a
c
m
c
w
a
p
f04  
or  example,  oxytocin  may  increase  maternal  temperature
ith  deleterious  consequences  for  both  mother  and  fetus  by
he  increased  secretion  stimulation  of  inﬂammatory  medi-
tors  (PGE  and  PGF2). However,  in  a  retrospective  study
f  pregnant  women  with  intrauterine  fetal  death  in  the  sec-
nd  trimester  of  pregnancy,  the  use  of  high-dose  oxytocin
0.267--1.667  IU  min−1)  did  not  determine  rise  in  maternal
emperature.11
Hemodynamic  changes  that  occur  during  cesarean  sec-
ion  have  multifactorial  causes,  such  as  sympathetic  nervous
ystem  blockade  secondary  to  the  spinal  anesthesia,  aorto-
aval  decompression  and  maternal  autotransfusion  after
lacental  delivery,  bleeding,  use  of  vasopressor,  etc.  The
se  of  oxytocin  is  just  one  of  these  causes  and  is  directly
ependent  on  the  way  it  is  administered  (dose  and  infusion
ate).
Human  vascular  endothelial  cell  has  oxytocin  recep-
ors  that  are  structurally  identical  to  receptors  present
n  myometrium  and  mammary  gland.12 The  interaction  of
xytocin  with  its  endothelial  receptor  determines  calcium-
ependent  response  via  nitric  oxide,  resulting  in  smooth
uscle  relaxation  of  resistance  and  capacitance  vessels.
hus,  vasodilation  is  the  primary  cardiocirculatory  event
fter  the  use  of  oxytocin.  Tachycardia,  increased  stroke
olume  and  cardiac  output  (CO)  occur  as  compensatory
echanisms  to  vasodilation.  These  effects  are  more  pro-
ounced  when  oxytocin  is  administrated  as  bolus  and
an  be  harmful  to  patients  with  impaired  cardiovascular
eserve.
The  use  of  high-dose  bolus  (e.g.,  5--10  IU  of  oxytocin)
as  frequently  been  discouraged,  particularly  after  reports
f  maternal  death  after  bolus  administration  of  oxytocin
10  UI)  to  hypovolemic  patient  due  to  uterine  atony,  accord-
ng  to  the  triennial  survey  of  maternal  death  occurred  in
he  UK.13
In  elective  cesarean  sections,  standard  non-invasive
onitoring  (ECG,  noninvasive  blood  pressure,  and  pulse
ximetry)  is  used,  which  may  not  detect  the  possible  hemo-
ynamic  changes  determined  after  the  use  of  oxytocin,
specially  because  they  are  most  pronounced  about  the
rst  minute  after  oxytocin  administration.  While  not  routine
uring  cesarean  section,  invasive  monitoring  methods  have
llowed  a  better  understanding  of  the  hemodynamic  proﬁle
f  these  patients  after  oxytocin  administration.  Langesaeter
t  al.14 with  invasive  monitoring  (LiDCOPlus® monitor)  in
ealthy  pregnant  women,  observed  an  increase  in  cardiac
ndex  (CI),  decreased  systemic  vascular  resistance  (SVR)
nd  systolic  blood  pressure  (BP)  (range  of  36--62  mmHg)  45  s
fter  oxytocin  injection.  This  same  group  of  authors  stud-
ed  18  patients  with  preeclampsia  who  underwent  cesarean
ection.15 With  the  same  monitoring  as  the  previous  study
LiDCOPlus®)  connected  to  the  radial  artery  of  patients,  the
uthors  found  increased  heart  rate  (HR)  and  decreased  SVR
nd  BP  in  all  patients  receiving  oxytocin  (5  IU)  after  delivery.
he  hemodynamic  instability  that  can  occur  during  postpar-
um  hemorrhage  may  not  be  solely  due  to  hypovolemia,  but
he  association  of  both  hypovolemia  and  use  of  oxytocin
olus.16Hemodynamic  changes  determined  by  oxytocin  are
irectly  dependent  on  dose  and  rate  of  infusion.  Thomas
t  al.17 found  that  bolus  administration  of  oxytocin  (5  IU
ver  5  s)  promotes  greater  decrease  in  mean  BP  and  greater
p
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ncrease  in  heart  rate  than  the  administration  of  oxytocin
5  IU  over  5  min)  in  patients  undergoing  elective  cesarean
ection.  The  authors  recommend  that  oxytocin  should  be
dministered  slowly  to  minimize  cardiovascular  effects  that
ay  not  be  well  tolerated  by  the  hypovolemic  patient  or
ith  low  cardiac  reserve.
The  administration  of  oxytocin  (5  IU  over  3  min)  as  a
oading  dose,  followed  by  oxytocin  infusion  (30  IU  over
 h)  did  not  determine  signiﬁcant  hemodynamic  changes
ompared  to  administration  of  the  same  loading  dose,  fol-
owed  by  placebo  infusion  (crystalloid  solution).18 With
he  thoracic  bioimpedance  method,  the  studied  parame-
ers  (CI,  left  ventricular  work  and  SVR)  were  gradually
eturning  to  preoperative  values  of  these  patients  during
he  4  h  of  oxytocin  infusion,  probably  due  to  spinal  block
egression.
ECG  changes  suggestive  of  myocardial  ischemia  have
een  reported  after  administration  of  oxytocin  bolus  (10  IU
ver  30  s)  after  clamping  the  umbilical  cord  during  elective
esarean  sections.19 These  changes  were  accompanied  by
ypotension,  tachycardia,  and  breast  discomfort,  but  were
eversible  and  of  short  duration.  However,  the  combination
f  hypotension,  tachycardia,  and  coronary  vasoconstriction
ay  cause  an  imbalance  between  myocardial  oxygen  sup-
ly  and  demand  and  possible  myocardial  ischemia,  even  in
atients  without  coronary  disease.
With  standard  monitoring,  changes  in  the  patient’s  HR
orrelate  better  with  changes  in  CO  compared  to  variations
n  pressure  values.  Sartain  et  al.20 demonstrated  a  greater
ncrease  in  HR  using  oxytocin  5  IU  compared  to  oxytocin  2  IU
32  ±  17  bpm  vs  24  ±  13  bpm,  respectively,  p  =  0.015).  These
oses  were  diluted  to  a  ﬁnal  volume  of  5  mL  and  infused  over
--10  s.  All  patients  received  oxytocin  infusion  (10  IU  h−1 over
 h)  after  loading  dose.
In  this  context  of  hemodynamic  changes  associated
ith  oxytocin,  Dyer  et  al.21 performed  an  important
tudy  comparing  maternal  hemodynamic  effects  after  the
se  of  phenylephrine  or  ephedrine  for  arterial  hypoten-
ion  management  after  spinal  anesthesia  in  cesarean
ections.  Twenty  patients  who  received  no  vasopres-
ors  (ephedrine)  were  randomized  to  receive  oxytocin
.5  IU  or  oxytocin  2.5  IU  associated  with  phenylephrine
80  g)  30  s  after  birth.  The  authors  concluded  that
henylephrine  alleviates  maternal  hemodynamic  effects
f  oxytocin.  Thus,  in  clinical  practice,  we  often  end
p  managing  possible  hemodynamic  effects  of  oxy-
ocin  when  a  direct  action  vasopressor  (phenylephrine
r  metaraminol)  is  used  in  the  treatment  of  maternal
ypotension  secondary  to  sympathetic  blockade  in  spinal
nesthesia.
As  can  be  seen,  the  hemodynamic  changes  that  could  be
aused  or  contributed  by  oxytocin  have  been  one  of  the
ajor  concerns  for  researchers  today.  The  clinical  signiﬁ-
ance  of  these  ﬁndings  still  seems  unclear,  as  the  effects
ere  transient  and  reversible  in  most  cases.  Oxytocin,  prob-
bly  determine  more  signiﬁcant  hemodynamic  changes  in
atients  who  had  low  heart  reserve  or  hypovolemia;  there-
ore,  the  use  of  oxytocin  bolus  in  this  particular  group  of
atients  should  be  avoided.22
According  to  the  National  Health  Surveillance  Agency
Anvisa),23 currently  oxytocin  can  be  found  in  Brazil  for  hos-
ital  use  under  the  following  names:  Syntocinon®,  Oxiton®,
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Table  1  What  should  I  learn  from  this  review.
Oxytocin  is  the  uterotonic  of  choice  for  the  prevention  and  treatment  of  uterine  atony
There is  no  consensus  on  the  optimum  dose  and  rate  of  its  administration  in  cesarean  sections
Drip infusion  of  oxytocin  (5--20  IU)  diluted  in  crystalloid  solution  seems  to  be  the  usual  mode  of  use  in  cesarean  sections  in
Brazil
The use  of  oxytocin  bolus  (e.g.,  10  IU)  should  be  avoided,  particularly  in  hypovolemic  patients  or  those  with  low
cardiovascular  reserve
High  doses  of  or  prolonged  exposure  to  oxytocin  can  lead  to  desensitization  of  its  receptors  and  be  translated  clinically  as
therapeutic inefﬁcacy
In case  of  response  failure  after  the  use  of  oxytocin,  consider  other  uterotonic  agents  (ergot  derivatives,  prostaglandins)
Carbetocin is  a  synthetic  analog  of  oxytocin,  but  with  a  half-life  four  times  longer,  and  no  therapeutic  dose  established  yet
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rNaox®,  Obstecina®,  Ocitoc®;  all  with  chlorobutanol  added
as  a  preservative  in  the  composition.  In  vitro  study  with
human  atrial  myocytes  showed  that  chlorobutanol  has  neg-
ative  inotropic  action.24
Desensitization of oxytocin receptors
In  2004,  Carvalho  et  al.25 demonstrated  that  oxytocin
ED90----the  effective  to  promote  satisfactory  uterine  con-
tractions  in  90%  of  patients----would  be  around  0.35  IU.  The
study  was  performed  with  patients  scheduled  for  elective
cesarean  section  without  risk  factors  for  uterine  atony,
with  the  logistic  regression  method.  Based  on  experimental
works  of  female  rat  myometrium,  the  same  group  conducted
a  study  with  similar  design,  but  now  involving  pregnant
women  who  underwent  cesarean  section  due  to  dystocia
and  who  received  oxytocin  during  labor.  In  such  cases,  it
was  found  an  increase  in  oxytocin  ED90 of  almost  ninefold
(2.9  IU).26 The  likely  explanation  for  these  results  would  be
the  occurrence  of  desensitization  of  oxytocin  receptors  in
myometrium  after  prolonged  exposure  to  oxytocin  during
labor.
Continuing  these  investigations,  Balki  et  al.27 studied
myometrium  fragments  of  pregnant  mice  and  found  a
decrease  in  the  amplitude  of  myometrial  contractions  when
these  fragments  were  previously  exposed  to  oxytocin  com-
pared  to  control  group  (saline).  Although  the  contractility
caused  by  oxytocin  was  higher  than  the  contractility  caused
by  ergonovine  or  PGF2,  the  uterotonic  effect  of  these
drugs  was  not  affected  by  prior  exposure  to  oxytocin.  This
study  supports  the  concept  of  desensitization  of  myometrial
receptors  after  prolonged  exposure  to  oxytocin.  Clinically,
these  results  demonstrate  that  high  doses  of  oxytocin  for
prolonged  periods  can  lead  to  a  lower  efﬁciency  of  utero-
tonic  action  or  even  uterine  atony.
Measurement of oxytocin in blood
There  are  few  studies  describing  oxytocin  levels  in  blood.
Usually  these  papers  involve  pregnant  women  in  labor,  or  are
experimental  animal  studies,  with  radioimmunoassay  (RIA)
for  oxytocin  measurement.
Serum  levels  of  oxytocin  by  enzyme  immunoassay  tech-
nique  (ELISA)  have  been  studied  in  pregnant  women
undergoing  elective  cesarean  section.28 Although  this  study
w
o
l
aas  not  designed  to  correlate  serum  doses  of  oxytocin  with
linical  efﬁcacy,  the  authors  demonstrated  that  the  use  of
xytocin  80  IU  (2.67  IU  min−1)  determined  serum  levels  of
xytocin  larger  at  5  and  30  min,  compared  with  the  use  of
0  IU  (0.33  IU  min−1 or  2.67  IU  min−1).  The  technique  used
ELISA)  had  the  advantage  of  handling  non-radioactive  mate-
ial,  compared  with  the  RIA  technique.  Furthermore,  the
anagement  of  peptides,  such  as  oxytocin,  requires  spe-
ial  care  because  storage  of  samples  should  be  at  −70 ◦C
o  prevent  oxytocin  degradation  by  maternal  aminopepti-
ases.
Additional  studies  should  be  developed  in  an  attempt
o  correlate  oxytocin  blood  measurement  with  satisfactory
terine  contractility  and  lower  incidence  of  side  effects.
pparently,  the  clinical  efﬁcacy  of  oxytocin  is  more  depend-
nt  on  its  interaction  with  its  receptor  than  actually  with  its
lood  concentration.
arbetocin
arbetocin,  a synthetic  analog  of  oxytocin,  has  the  same
fﬁnity  as  oxytocin  for  myometrial  receptors,  but  differs  for
aving  a much  longer  plasma  half-life  than  oxytocin  (40  min
s.  15  min,  respectively),  which  has  aroused  special  inter-
st  as  an  option  to  the  use  of  oxytocin  to  prevent  uterine
tony.29
Cordovani  et  al.30 used  carbetocin  at  doses  of  80  g  and
20  g  in  patients  with  low  risk  of  postpartum  bleeding  and
ho  underwent  elective  cesarean  section.  In  these  patients,
he  uterine  tone  was  satisfactory  in  87%  of  cases;  there
as  no  signiﬁcant  difference  between  the  doses  used.  The
uthors  reported  a  high  incidence  (55%)  of  hypotension  with
hese  doses,  since  carbetocin  has  a  hemodynamic  proﬁle
imilar  to  that  of  oxytocin.  Moertl  et  al.31 in  a  prospec-
ive  randomized  study  of  56  women  undergoing  elective
esarean  section,  compared  bolus  doses  (10  s)  of  carbe-
ocin  (100  g)  with  oxytocin  (5  IU).  There  was  an  increase
n  HR  (14.20  ±  2.45  bpm  vs.  17.98  ±  2.53  bpm,  respectively)
nd  decrease  in  BP  in  both  groups,  especially  after  30--40  s
f  administration  of  each  of  these  uterotonic  drugs.  These
esults  are  comparable  to  those  found  by  Rosseland  et  al.,32ho  used  the  same  doses  (5  IU  of  oxytocin  and  100  g
f  carbetocin,  in  addition  to  a  placebo  group)  in  a  simi-
ar  group  of  patients,  but  invasively  monitored  with  radial
rtery  catheterization.  In  Brazil,  carbetocin  is  registered
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206  
ith  Anvisa  under  the  trade  name  Duratocin® in  1  mL  vials
100  g  mL−1).23 However,  other  studies  should  be  developed
o  establish  the  effective  dose  of  carbetocin  and  if  its  use
educes  the  postpartum  incidence  of  bleeding  or  the  need
or  blood  transfusion.
Finally,  the  essential  points  of  this  review  may  be  seen  in
able  1.
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